A major yet unresolved quest in decoding the human genome is the identification of the regulatory sequences that control the spatial and temporal expression of genes. Distant-acting transcriptional enhancers are particularly challenging to uncover because they are scattered among the vast non-coding portion of the genome. Evolutionary sequence constraint can facilitate the discovery of enhancers, but fails to predict when and where they are active in vivo. Here we present the results of chromatin immunoprecipitation with the enhancer-associated protein p300 followed by massively parallel sequencing, and map several thousand in vivo binding sites of p300 in mouse embryonic forebrain, midbrain and limb tissue. We tested 86 of these sequences in a transgenic mouse assay, which in nearly all cases demonstrated reproducible enhancer activity in the tissues that were predicted by p300 binding. Our results indicate that in vivo mapping of p300 binding is a highly accurate means for identifying enhancers and their associated activities, and suggest that such data sets will be useful to study the role of tissue-specific enhancers in human biology and disease on a genome-wide scale.
The initial sequencing of the human genome 1,2 , complemented by effective computational and experimental strategies for mammalian gene discovery 3, 4 , has resulted in a virtually complete list of proteincoding sequences. In contrast, the genomic location and function of regulatory elements that orchestrate gene expression in the developing and adult body remain more obscure, hindering studies of their contribution to developmental processes and human disease. Evolutionary constraint of non-coding sequences can predict the location of enhancers in the genome [5] [6] [7] [8] [9] [10] [11] [12] , but does not reveal when and where these enhancers are active in vivo. Furthermore, it has been suggested that a substantial proportion of regulatory elements is not sufficiently conserved to be detectable by comparative genomic methods [13] [14] [15] [16] . Chromatin immunoprecipitation coupled to massively parallel sequencing (ChIP-seq) has been shown to enable genome-wide mapping of protein binding and epigenetic marks [17] [18] [19] [20] [21] [22] . The ChIP-seq approach is dependent on the cross-linking of proteins to specific DNA elements, followed by antibody enrichment of the protein-DNA complexes, and high-throughput sequencing of the recovered DNA fragments. In principle, ChIP-seq using an antibody specific for an enhancer-binding protein could provide a conservation-independent approach for the identification of candidate enhancer sequences.
The acetyltransferase and transcriptional coactivator p300 is a near-ubiquitously expressed component of enhancer-associated protein assemblies and is critically required for embryonic development [23] [24] [25] [26] [27] . In homogeneous cell preparations, p300 has been shown to be associated with enhancers 28, 29 , but these in vitro studies provided access only to subsets of enhancers that are active in a given cell type under culture conditions, providing limited insight into their in vivo function. In the present study, we have determined the genome-wide occupancy of p300 in forebrain, midbrain and limb tissue isolated directly from developing mouse embryos. Using a transgenic mouse reporter assay, we show that p300 binding in these embryonic tissues predicts with high accuracy not only where enhancers are located in the genome, but also in what tissues they are active in vivo. Depending on the tissue type, the success rate of predicting forebrain, midbrain and limb enhancers was between 5-and 16-fold increased compared to previous studies in which such enhancers were discovered by comparative genomics 10, 11 .
Genome-wide mapping of p300 in tissues To generate genome-wide maps of p300 binding in vivo, we microdissected forebrain, midbrain and limb tissue from more than 150 embryonic day 11.5 (E11.5) mouse embryos and performed ChIP directly from these tissue samples using a p300 antibody (Fig. 1) . Immunoprecipitated DNA fragments were analysed using massively parallel sequencing and the resulting 36 base pair (bp) sequence reads were aligned to the reference mouse genome 17, 30 . After appropriate quality filtering, between 2.4 and 3.6 million aligned reads obtained from each of the tissue samples were used to identify regions of the genome with significant enrichment in p300-associated DNA sequences, hereafter referred to as 'peaks' owing to their appearance in genome-wide density plots 17 (Supplementary Table 1 ). Using an estimated false-discovery rate (FDR) threshold of ,0.01, we identified 2,543, 561 and 2,105 peaks from forebrain, midbrain and limb respectively (Supplementary Tables  2-4) . Most peaks were located at least 10 kb from transcript start sites ( Supplementary Fig. 1 ). The smaller number of peaks from midbrain is probably due to variability in the efficiency of enrichment by ChIP ( Supplementary Fig. 2 ). Re-sampling of subsets of data suggests that the major p300-binding sites from these three tissues have been discovered, whereas with increased sequencing coverage it is anticipated that further binding sites can be identified that are occupied only in smaller subsets of cells within each tissue (Supplementary Fig. 3 ). Although most genomic regions with in vivo p300 binding were identified by peaks in a single tissue, there were 386 regions at which peaks were observed in two tissues, and 21 regions at which p300 peaks were observed in all three tissues ( Supplementary Fig. 4 ). p300 predicts enhancer activity patterns To test directly whether p300 binding in developing mouse tissues is indicative of enhancer activity in vivo, we selected 86 regions with a p300 peak in at least one of the tissues for analysis in transgenic mice, comprising a total of 122 individual predictions of enhancer activity in specific tissues (Supplementary Table 5 ). These elements were selected blind to the identity of genes near which they are located, showed a wide range of evolutionary conservation with other vertebrate species (see Methods) and approximately reflect the genome-wide distribution properties of p300 peaks among intronic and intergenic regions, as well as their distances relative to known genes (Supplementary Fig. 1) .
We cloned the human genomic sequences orthologous to these enhancer candidate regions into an enhancer reporter vector and generated transgenic mice as previously described 10, 31 . For each of the 86 candidate enhancers, several independent transgenic embryos (average of n 5 8) were assessed for reproducible reporter gene expression. A pattern was considered reproducible if the same anatomical structure was stained in three or more embryos. In almost all cases, this minimum threshold was exceeded and reproducible reporter staining in forebrain, midbrain or limb was present on average in more than 80% of the embryos obtained per construct (Supplementary Table 5 ).
First we determined whether p300 binding was predictive of reproducible in vivo enhancer activity regardless of their tissue specificity. Considering peaks from each of the three p300 data sets separately, 55 out of 63 (87%) forebrain predictions, 30 out of 34 (88%) midbrain predictions and 22 out of 25 (88%) limb predictions were active enhancers in vivo at E11.5 as defined by reproducible LacZ staining (Fig. 2 , grey and coloured bars). Overall, 87% (75 out of 86) of the tested elements were reproducible enhancers at E11.5. This compares with a success rate for predicting enhancers of 47% (246 out of 528) from our previous studies in which elements were identified on the basis of their extreme evolutionary conservation and tested using the same transgenic mouse assay 10, 11 . Thus, the rate of false-positive predictions using p300 ChIP-seq was more than fourfold lower than that with extreme evolutionary conservation (13% compared to 53% previously; P 5 4.2 3 10 210 , Fisher's exact test). We next determined the accuracy with which p300 binding predicts the tissue in which enhancer activity will occur. Of the 63 tested elements that overlapped a forebrain p300 peak, 49 (78%) were found to have reproducible enhancer activity in the developing forebrain (Fig. 2 , blue). Similarly, 28 out of 34 (82%) tested elements identified by midbrain p300 enrichment (Fig. 2, red) , and 20 out of 25 (80%) tested elements identified by limb p300 enrichment (Fig. 2, green) , were confirmed to be active in the predicted tissue. The 86 tested elements included 32 sequences that were identified by p300 binding in more than one tissue. Of these, 27 out of 32 (84%) were active in at least one of the predicted tissues, and 22 sequences (69%) perfectly recapitulated the predicted expression patterns (Supplementary Table 6 ).
To assess the degree of enrichment of enhancer activities in predicted tissues, we compared the relative frequency of enhancers for each of the three tissues examined here with a background set of 528 previously tested sequences predicted to be developmental enhancers on the basis of extreme sequence constraint that were not associated with a prior tissue specificity prediction 10, 11 . For example, whereas forebrain enhancers account for only 16% (86 out of 528) of the tested elements identified through comparative approaches, 78% (49 out of 63) of elements predicted by forebrain p300 peaks were found to be active enhancers in the forebrain (Fig. 2) . Forebrain predictions are therefore fivefold enriched in forebrain enhancers compared with enhancers identified through comparative approaches (P , 1 3 10
222
). Similarly, we observed a sixfold enrichment of midbrain enhancers (P , 1 3 10
211
) and a 16-fold enrichment of limb enhancers (P , 1 3 10
218
) at midbrain and limb p300 peaks, respectively. Representative examples of enhancers identified by ChIP-seq are shown in Fig. 3 and detailed annotations and reproducibility across transgenic mice for all elements tested in this study can be found at http://enhancer.lbl.gov (ref. 32) . Taken together, these results indicate that p300 peaks are a highly accurate predictor of in vivo enhancers and their spatial activity patterns. ARTICLES Most p300-bound regions are conserved Previous studies have indicated a positive correlation between enhancer activity during development and non-coding sequence conservation 6, [8] [9] [10] [11] 33 , but it has also been suggested that not all regulatory elements in vertebrate genomes are under detectable evolutionary constraint [13] [14] [15] [16] . To test whether p300 binding in E11.5 tissues is generally associated with evolutionarily constrained non-coding sequences, we determined if ChIP-seq reads are overall enriched at previously identified extremely conserved non-coding sequences 9, 11 . We observed strong enrichment of p300 ChIP-seq reads at these conserved sequences, but not at random sites or exons (Fig. 4 and Supplementary Table 7) . Vice versa, between 86% and 91% of the p300 peaks overlap sequences that are under evolutionary constraint in vertebrates 34 , compared to less than 30% of size-matched random regions (P , 1 3 10 2172 , Fisher's exact test; Supplementary Fig. 5 ). Using a more stringent constraint threshold score, we observed that between 10% and 21% of peaks are highly constrained, compared to 1% of random regions (P , 1 3 10
282
). These results indicate that most p300 peaks in the investigated tissues are under evolutionary constraint and support a global enrichment of p300 in highly conserved non-coding regions of the genome previously correlated with developmental enhancers.
Correlation with gene expression patterns
To examine the correlation of p300-enriched regions in embryonic tissues with the transcriptional regulation of neighbouring genes, we compared the genomic distribution of p300 peaks in E11.5 forebrain with gene expression data from this tissue. Using high-density microarrays, we identified a set of 885 genes that are overexpressed in forebrain at E11.5 compared to whole embryos (Supplementary Table 8 ).
When we compared the genomic position of these forebrain genes to the genome-wide distribution of 2,453 forebrain-derived p300 peaks, we observed that the intervals 90 kb up-and downstream of their promoters are 2.4-fold enriched overall in p300-binding sites (P , 0.05, Fig. 5a ). In total, 14% of all forebrain p300 peaks are located within 101 kb from a promoter of a forebrain-overexpressed gene. The most Figure 4 | In all tissues examined, p300 is enriched at highly conserved non-coding regions. We used a genome-wide set of 50,000 extremely constrained non-coding sequences identified in human-mouse-rat genome alignments 11 to assess the correlation between p300 enrichment and noncoding sequence conservation. Even though only subsets of the constrained non-coding elements are expected to be active enhancers in any given embryonic tissue, we observe strong enrichment in p300 binding in all three tissues compared to input DNA. *P , 1 3 10 2100 , Fisher's exact test. Relative p300 coverage near random sites and internal exons is shown for comparison. Brown bars indicate the median sizes of conserved elements or exons (124 bp in both cases). For further details, see Supplementary Table 7. pronounced enrichment (4.8-fold, P , 0.01) was observed within 10 kb up-and downstream of promoters of forebrain-specifically expressed genes. In contrast, forebrain peaks are not enriched near genes overexpressed in other parts of the body (Fig. 5b, Supplementary Table 9 ). Near genes that were overexpressed fivefold or more in the forebrain, even higher enrichment of forebrain peaks was observed (11-fold enrichment within 10 kb from promoters, data not shown). We found similar enrichment of limb-derived p300 peaks near limboverexpressed genes ( Supplementary Fig. 6 and Supplementary Tables  10 and 11 ). These observations are consistent with the sequences bound by p300 in the forebrain or limb of day 11.5 embryos being enhancers that drive the expression of adjacent genes in these tissues at this time point.
Discussion
In the present study, we have determined the genome-wide distribution of the transcriptional coactivator protein p300 (ref. 23) using ChIPseq 17 directly from developing mouse tissues. Notably, enrichment of p300 in different mouse tissues correctly predicted the spatial enhancer activities of human non-coding sequences in 80% of cases tested in a transgenic mouse assay, whereas absence of p300 enrichment correlated in 93% of cases with absence of enhancer activity in the respective tissue (Supplementary Table 5 ). The few elements that did not drive reporter gene expression in the tissue predicted by p300 ChIP-seq may represent cases in which the function of regulatory elements has diverged between the mouse sequences identified by ChIP-seq and the human orthologous regions tested in the transgenic mouse assay. In support of this hypothesis, we observed several cases in which the non-coding p300-bound region from mouse, but not the orthologous human sequence, had reproducible enhancer activities as predicted by p300 ChIP-seq from mouse tissues (data not shown). Taken together, the present approach provides a markedly improved specificity for locating enhancers in the human genome compared to conservationbased methods 10, 11 and also predicts their in vivo activity patterns with higher accuracy than motif-based computational methods available at present (for example, refs 35, 36) .
Most p300-binding regions identified in developing mouse tissues are under detectable evolutionary constraint. They typically overlap conserved non-coding sequences whose length (median of 113 bp) far exceeds that of an individual transcription factor binding site, suggesting the presence of larger functional modules. In cell culture-based chromatin studies, a sizeable fraction of non-coding regions in the human genome was found to be functional yet not constrained 13, 14 . This apparent discrepancy might be due to differences in evolutionary constraint between enhancers active in developing tissues compared to those in individual cell types, but highlights the intrinsic challenge of inferring in vivo functionality from studies in cell culture.
A generalized picture of the epigenetic marks and proteins associated with different types of functional non-coding elements has started to emerge from genome-wide chromatin studies 13, 18, 28, [37] [38] [39] [40] [41] .
We can now begin to use these signatures to unravel gene regulation on a genomic scale in the context of living organisms. The highly specific approach for identification of developmental enhancers and their activity patterns presented here represents a step in this direction.
Complementary in-vivo-derived genomic data sets may be produced in the future, covering additional embryonic stages, anatomical regions and subregions, and perhaps considering extra molecular markers 28, [42] [43] [44] [45] . Focused experiments informed by such insights will expedite studies of the genome-wide activity dynamics of enhancers in developmental, physiological and pathological processes.
METHODS SUMMARY
Embryonic forebrain, midbrain and limb tissue was isolated from mouse embryos at E11.5. Cross-linking, chromatin isolation, sonication and immunoprecipitation using an anti-p300 antibody were performed as previously described 40, 46 . ChIP DNA was further sheared by sonication, end-repaired, ligated to sequencing adapters and amplified by emulsion PCR as previously described 47 . Gel-purified amplified ChIP DNA between 300 and 500 bp was sequenced on the Illumina Genome Analyzer II platform to generate 36-bp reads.
Sequence reads were aligned to the mouse reference genome (mm9) using BLAT 48 . Uniquely aligned reads were extended to 300 bp in the 39 direction and used to determine the read coverage at individual nucleotides at 25-bp intervals throughout the mouse genome. p300-enriched regions (peaks) with an estimated FDR of # 0.01 were identified by comparison with a random distribution of the same number of reads. Candidate peaks mapping to repetitive regions were removed as probable artefacts.
Candidate regions for transgenic testing were selected based on ChIP-seq results and cover a wide spectrum of conservation. Enhancer candidate regions were amplified by PCR from human genomic DNA and cloned into an Hsp68-promoter-LacZ reporter vector as previously described 6, 31 . Transgenic mouse embryos were generated and evaluated for reproducible LacZ activity at E11.5 as previously described 6 . Total RNA from E11.5 whole embryos and forebrain tissue was hybridized to GeneChip Mouse Genome 430 2.0 arrays (Affymetrix) and analysed according to the manufacturer's recommendations. Forebrain-and whole-embryo-enriched genes were identified as having at least 2.5-fold greater expression in one data set compared with the other, and a minimum signal intensity of 100. Limb-enriched genes were identified by comparison with publicly available wild-type E11.5 proximal hindlimb gene expression data (Gene Expression Omnibus (GEO) series GSE10516, samples GSM264689, GSM264690 and GSM264691) 49 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. We compared the genome-wide distribution of p300-enriched regions in forebrain tissue at E11.5 with microarray expression data for forebrain at the same stage. Eight-hundred-and-eighty-five genes were forebrain-specifically overexpressed, and 495 genes were underexpressed relative to whole embryo RNA at the selected thresholds. Promoters (defined as 1 kb upstream and downstream of transcription start sites) were excluded from the analysis. Blue bars denote comparison to 2,435 forebrain-derived peaks, grey bars denote comparison to 2,435 random sites. a, Ten-kilobase bins up to 91 kb away from forebrain-overexpressed genes were significantly enriched in forebrain p300 peaks. b, No peak enrichment was observed for forebrain-underexpressed genes. Error bars indicate the 90% confidence interval on the basis of 1,000 iterations of randomized distribution. *P , 0.05, **P , 0.01, both one-tailed. 
